What caused the GNCA stock drop today?

GNCA stock fell to **$0.0001** mainly from low liquidity, prior restructuring, and absence of new clinical or financing news. Small order flows can move the price sharply when average volume is under **81,000** shares.

Does Genocea have cash to continue operations?

Genocea reports cash per share of **0.54** and a current ratio of **2.24**, indicating some short-term liquidity. However, negative operating cash flow per share **-0.66** shows ongoing cash burn and high funding risk.

What is Meyka AI's stance on GNCA stock?

Meyka AI rates GNCA with a score out of 100: **58.60**, grade **C+ (HOLD)**. The grade factors benchmarking, sector metrics, financial growth, key ratios, and forecasts. This is informational, not investment advice.

Is there a price target for GNCA stock?

Public analyst coverage is absent. Meyka AI's forecast model projects **$0.0010** as a base case, implying **+900.00%** from **$0.0001**. Forecasts are model-based projections and not guarantees.

US Stocks

GNCA stock falls to $0.0001 on NASDAQ 20 Jan 2026: catalysts and outlook

ByHuzaifa Zahoor January 21, 2026

GNCA stock moved sharply lower intraday, trading at $0.0001 on NASDAQ in the United States on 20 Jan 2026 after steep prior declines. Genocea Biosciences, Inc. (GNCA) saw volume of 30,268 shares versus a 50-day average of 80,568, signaling low liquidity and high volatility. The drop follows a prolonged post-restructuring slide and thin trading, making short-term price moves driven more by trading flows than by fresh clinical data.